Nordic Nanovector ASA logo

NANO - Nordic Nanovector ASA Share Price

NOK13.33 -0.2  -1.3%

Last Trade - 12:25pm

Sector
Healthcare
Size
Small Cap
Market Cap £77.2m
Enterprise Value £56.9m
Revenue £n/a
Position in Universe 844th / 1789
Bullish
Bearish
Unlock NANO Revenue
Momentum
Relative Strength (%)
1m -16.1%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -61.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.44 0.44 0.31 0.30 0.000 0.000 -100.0%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, NordicNanovector ASA revenues was not reported. Net lossincreased 8% to NOK218.4M. Higher net loss reflects Otheroperating expenses increase of 24% to NOK191.8M (expense),Foreign Exchange Gain/Loss–Non-Busine decrease from NOK447K(income) to NOK12.5M (expense), Depreciation increase of61% to NOK7.4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

NANO Revenue Unlock NANO Revenue

Net Income

NANO Net Income Unlock NANO Revenue

Normalised EPS

NANO Normalised EPS Unlock NANO Revenue

PE Ratio Range

NANO PE Ratio Range Unlock NANO Revenue

Dividend Yield Range

NANO Dividend Yield Range Unlock NANO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
NANO EPS Forecasts Unlock NANO Revenue
Profile Summary

Nordic Nanovector ASA is a Norway-based company active in the biotechnology industry. It is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product candidate is Betalutin, comprising a tumor-seeking anti-CD37 antibody conjugated to a low intensity radionuclide (Lutetium 177). It is designed improve treatment of Non-Hodgkin Lymphoma (NHL) and advanced through clinical development. Additionally, the Company is engaged in the development of its Antibody-Radionuclide-Conjugate (ARC) portfolio to treat various selected cancer indications. It has two subsidiaries, Nordic Nanovector GmbH and Nordic Nanovector Ltd.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated July 7, 2009
Public Since July 7, 2014
No. of Shareholders: 10,401
No. of Employees: 44
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Oslo Stock Exchange
Shares in Issue 68,447,656
Free Float (0.0%)
Eligible for
ISAs
SIPPs
NANO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for NANO
Upcoming Events for NANO
Frequently Asked Questions for Nordic Nanovector ASA
What is the Nordic Nanovector ASA share price?

As of 12:25pm, shares in Nordic Nanovector ASA are trading at NOK13.33, giving the company a market capitalisation of £77.2m. This share price information is delayed by 15 minutes.

How has the Nordic Nanovector ASA share price performed this year?

Shares in Nordic Nanovector ASA are currently trading at NOK13.33 and the price has moved by -35.16% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Nordic Nanovector ASA price has moved by -26.51% over the past year.

What are the analyst and broker recommendations for Nordic Nanovector ASA?

Of the analysts with advisory recommendations for Nordic Nanovector ASA, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Nordic Nanovector ASA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Nordic Nanovector ASA next release its financial results?

Nordic Nanovector ASA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Nordic Nanovector ASA dividend yield?

Nordic Nanovector ASA does not currently pay a dividend.

Does Nordic Nanovector ASA pay a dividend?

Nordic Nanovector ASA does not currently pay a dividend.

When does Nordic Nanovector ASA next pay dividends?

Nordic Nanovector ASA does not currently pay a dividend.

How do I buy Nordic Nanovector ASA shares?

To buy shares in Nordic Nanovector ASA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Nordic Nanovector ASA?

Shares in Nordic Nanovector ASA are currently trading at NOK13.33, giving the company a market capitalisation of £77.2m.

Where are Nordic Nanovector ASA shares listed? Where are Nordic Nanovector ASA shares listed?

Here are the trading details for Nordic Nanovector ASA:

Country of listing: Norway
Exchange: OSL
Ticker Symbol: NANO
What kind of share is Nordic Nanovector ASA?

Based on an overall assessment of its quality, value and momentum, Nordic Nanovector ASA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Nordic Nanovector ASA share price forecast 2020?

Shares in Nordic Nanovector ASA are currently priced at NOK13.33. At that level they are trading at 0.18% discount to the analyst consensus target price of 0.00.

Analysts covering Nordic Nanovector ASA currently have a consensus Earnings Per Share (EPS) forecast of -6.105 for the next financial year.

How can I tell whether the Nordic Nanovector ASA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nordic Nanovector ASA. Over the past six months, the relative strength of its shares against the market has been -32.57%. At the current price of NOK13.33, shares in Nordic Nanovector ASA are trading at -33.35% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Nordic Nanovector ASA PE Ratio?

We were not able to find PE ratio data for Nordic Nanovector ASA.

Who are the key directors of Nordic Nanovector ASA?

Nordic Nanovector ASA's management team is headed by:

Jostein Dahle - CSO
Per Samuelsson - DRC
Hilde Hermansen Steineger - IND
Marco Renoldi - COO
Jean-Pierre Bizzari - IND
Joanna Horobin - IND
Malene Brondberg - CFO
Rainer Boehm - IND
Jan Egberts - CHM
Lars Nieba - CEO
Rosemarie Corrigan - OTH
Gabriele Elbl - VPR
Dominic Smethurst - OTH
Christine Wilkinson Blanc - OTH
Who are the major shareholders of Nordic Nanovector ASA?

Here are the top five shareholders of Nordic Nanovector ASA based on the size of their shareholding:

HealthCap AB Venture Capital
Percentage owned: 7.77% (6.17m shares)
Folketrygdfondet Pension Fund
Percentage owned: 4.71% (3.74m shares)
OM Holding AS Corporation
Percentage owned: 3.72% (2.95m shares)
Nordea Funds Oy Investment Advisor
Percentage owned: 1.81% (1.44m shares)
KLP Forsikring Pension Fund
Percentage owned: 1.56% (1.24m shares)
Similar to NANO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.